Following a feud with activist investor Deep Track Capital in the first half of 2025, vaccine developer Dynavax Technologies ...

Johnson & Johnson’s $14.6 billion buyout of Intra-Cellular in the first mo | Of the top 10 biopharma M&A deals of 2025, six ...

A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several ...

A court in Baltimore has ordered Johnson & Johnson to pay $1.56 billion to a Maryland woman who claimed that her use of the company’s baby powder caused her cancer. It is the largest award ever ...

Pharma giant AstraZeneca has expanded its supply deal with Michigan-based medical radioisotope producer Niowave, establishing ...

When looking back at one of the most disruptive years in biopharma in recent memory, sev | Drug pricing, layoffs, personnel moves and other topics drove reader interest all year long. Here's a look at ...

Just days after an upbeat R&D event, Neurocrine Biosciences has found itself having to report a phase 3 failure. | Neurocrine’s Ingrezza, approved to treat certain uncontrolled movements, failed to ...